For patients with ER+ breast cancer exhibiting high levels of TRIM33 and ER, TRIM33 inhibition may be considered a therapeutic opportunity to downregulate ER and prevent estrogen-independent tumor growth, as is observed upon resistance to aromatase inhibitor therapy. Here, CYP19A1 is linked to breast cancer.